Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Italy, Spain, Japan, China, India, Australia, Mexico, Brazil, Saudi Arabia, South Africa), Application Development Potential, Price Trends, Competitive Market Share & Forecast, 2018 – 2024
Report ID: GMI3038
Paroxysmal nocturnal hemoglobinuria (PNH) treatment market size is expected to grow significantly from 2018 to 2024.
Paroxysmal nocturnal hemoglobinuria (PNH) treatment market will experience lucrative growth over the coming years due to increasing incidences of bone marrow and blood related disorders. According to National Organization for Rare Diseases (NORD), around 0.5-1.5 per million general population suffer from PNH.
Significant investment towards development of novel therapeutic compounds to treat paroxysmal nocturnal hemoglobinuria (PNH) should accelerate business growth. Apellis Pharmaceuticals, a clinical-stage biopharmaceutical company has currently commenced with PEGASUS phase 3 trial for assessing efficacy and safety of APL-2 therapy in PNH patients.
Associations such as The Canadian Association of PNH Patients (PNHCA) functions to create awareness regarding the disorder should support industry growing during the forecast period. As per the PNHCA, presently 10 organizations globally are conducting clinical trials to develop effective treatment for Paroxysmal nocturnal hemoglobinuria (PNH), thereby fueling industry growth. However, adverse effects associated with currently available treatments and lack of reimbursement policies in developing countries will hinder industry expansion to certain extent over the coming years.
Based on treatment, the industry is bifurcated into stem cell transplantation, blood transfusion and medication. Medication segment will experience lucrative growth during the forecast period owing to increasing investment towards developing effective treatment for PNH as well as high adoption of Soliris (eculizumab) to treat atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria.
Development of novel treatments including recombinant proteins, monoclonal antibodies, and cyclic peptides especially in developed countries of North America and Europe should drive industry growth. Pharmaceutical and biotech companies’ end-user segment is estimated to grow significantly during the forecast period due to high investment made by companies for developing superior treatment for PNH.
Growing demand for novel therapeutics, strong product pipeline and rising healthcare expenditure will drive North America paroxysmal nocturnal hemoglobinuria treatment market. Increasing incidences of blood related disorders in the country will positively impact business growth. Around 400-500 people annually are diagnosed with PNH in the U.S.
Development of healthcare system, growing disposable income coupled with unmet need of proper treatment for paroxysmal nocturnal hemoglobinuria should drive Asia Pacific market during the forecast period. Growing awareness as well as rising number of people suffering from conditions related with blood and bone marrow should positively affect Asia Pacific paroxysmal nocturnal hemoglobinuria treatment industry growth.
Major industry players such as Roche, Akari Therapeutics, Alexion Pharmaceuticals, Ra Pharmaceuticals, Novartis Pharmaceuticals, Alnylam, Apellis Pharmaceuticals, Achillion Pharmaceuticals, and Regeneron Pharmaceuticals compete in paroxysmal nocturnal hemoglobinuria (PNH) treatment market. These companies are focused towards developing effective treatment for PNH for which the companies are collaborating with research institutes and laboratories.
Paroxysmal nocturnal hemoglobinuria (PNH) treatment market, by treatment, 2013-2024 (USD Million)
- Stem cell transplantation
- Blood transfusion
Paroxysmal nocturnal hemoglobinuria (PNH) treatment market, by end-user, 2013-2024 (USD Million)
- Pharmaceutical and biotech companies
- Academic & research institutes
The above information is provided for the following regions and countries:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- Saudi Arabia
- South Africa
- Akari Therapeutics
- Alexion Pharmaceuticals
- Ra Pharmaceuticals
- Novartis Pharmaceuticals
- Apellis Pharmaceuticals
- Achillion Pharmaceuticals
- Regeneron Pharmaceuticals
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability
Why Global Market Insights?Comprehensive Research
- All-inclusive coverage
- In-depth and granular data (ex: information for 8 to 15 countries, with clients open to add to this list, in each report)
- Penetrative insights & latest trends
- Offers holistic understanding of the market
- Unique methodology
- Iterative in nature to eliminate errors
- Detailed methodology, scope, assumptions and data sources available for reference
- Committed to making a positive difference for our clients
- Given the nature of this industry, we are committed to ensure that our clients get maximum return on their investment in our services
- Every purchase comes with an option to obtain additional information:
- up to 10% of the original cost
- 45-minute analyst tele-call to obtain further clarity on the market.
- Global Market Insights, Inc. strictly adheres to PCI-DSS security norms.
- Only PCI-DSS compliant payment methods used for highest level of client data security
Connect with our sales team